Efficacy of Inhaled Colistin versus Oral Azithromycin in Preventing Exacerbation among Patients with Non-Cystic Fibrosis Bronchiectasis: A Retrospective Study

Abstract

Background: Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung condition that causes ongoing inflammation of the airways of the lungs, multiple lung infections and progressive airway structural damage, resulting in repeated exacerbations and poor quality of life. Recurrent exacerbation should be treated with long-term antibiotics, especially those with chronic Gram-negative bacterial colonization. Oral azithromycin is the most commonly used treatment; it is an antimicrobial and immunomodulatory agent, while inhaled colistin